Bayer: positive results for Eylea 8 mg in DME

(CercleFinance.com) - Results from PHOTON's open-label extension study show that diabetic macular edema (DME) patients randomized to Eylea 8 mg maintained visual and anatomical improvements after three years.


Patients who switched to Eylea 8 mg demonstrated significantly slower fluid re-accumulation after their first dose of Eylea 8 mg, compared with their previous rate of fluid re-accumulation with Eylea 2 mg. The safety profile of Eylea 8 mg remained favorable into the third year.

These long-term results are unprecedented and demonstrate that Eylea 8 mg achieves durable disease control with extended treatment intervals for the vast majority of patients in a setting similar to real-world clinical practice, a related source at Stanford University, said.

Based on the positive data, Eylea 8 mg has the potential to become the new reference treatment in diabetic macular edema.


Copyright (c) 2024 CercleFinance.com. All rights reserved.